TABLE 5.
Traditional antibacterial agents in clinical development for the treatment of TB and nontuberculous mycobacteria (NTM)
| Name (synonym) | Phase | Antibiotic class | Route of administration | Developer | Innovationa |
|||
|---|---|---|---|---|---|---|---|---|
| NCR | CC | T | MoA | |||||
| GSK-3036656 (GSK070) | 2 | Oxaborole (Leu-Rs inhibitor) | Oral | GSK | ✓ | ✓ | ✓ | ✓ |
| Delpazolid (LCB01-0371) | 2b | Oxazolidinone | Oral | LegoChem Biosciences/HaiHe Biopharma | — | — | — | — |
| Sutezolid | 2 | Oxazolidinone | Oral | TB Alliance/Sequella | — | — | — | — |
| Telacebec (Q-203) | 2 | Imidazopyridine amide | Oral | Qurient | ✓ | ✓ | ✓ | ✓ |
| TBA-7371 | 2 | Azaindole (DprE1 inhibitor) | Oral | TB Alliance/Bill & Melinda Gates Foundation/Foundation for Neglected Disease Research | ✓ | ✓ | ✓ | ✓ |
| SPR720 | 2ab | Benzimidazole ethyl urea (GyrB inhibitorc) | Oral | Spero/Bill & Melinda Gates Foundation | — | ✓ | — | — |
| TBI-166 (pyrifazimine)d | 2 | Riminophenazine (clofazimine-analogue) | Oral | Institute of Materia Medica/TB Alliance/Chinese Academy of Medical Sciences/Peking Union Medical College | — | — | — | — |
| OPC-167832 | 1/2 | 3,4-Dihydrocarbostyril (DprE1 inhibitor) | Oral | Otsuka | ✓ | ✓ | ✓ | ✓ |
| BTZ-043 | 1/2 | Benzothiazinone (DprE1 inhibitor) | Oral | University of Munich/Hans Knöll Institute, Jena/German Center for Infection Research | ✓ | ✓ | ✓ | ✓ |
| Macozinone (PBTZ-169) | 1 | Benzothiazinone (DprE1 inhibitor) | Oral | Innovative Medicines for Tuberculosis Foundation/Nearmedic Plus | ✓ | ✓ | ✓ | ✓ |
| TBI-223 | 1 | Oxazolidinone | Oral | TB Alliance/Institute of Materia Medica | — | — | — | — |
| TBAJ-876 | 1 | Diarylquinoline | Oral | TB Alliance | — | — | — | — |
| TBAJ-587 | 1 | Diarylquinoline | Oral | TB Alliance | — | — | — | — |
| GSK 2556286 (GSK-286) | 1 | Undisclosed | Oral | GSK/TB Drug Accelerator/Bill & Melinda Gates Foundation | ? | ✓ | ✓ | ? |
a
Innovation assessment: ✓, criterion fulfilled; ?, inconclusive data; —, criterion not fulfilled. CC, chemical class; MOA, new mode of action; NCR, no cross-resistance; T, new target.
b
This phase 2a trial (NCT04553406) was on FDA clinical hold, but this was lifted in January 2022.
c
This is not considered to be a new mode of action, as the GyrB/ParE inhibitor novobiocin was once marketed but is no longer in clinical use.
d
The lead drug clofazimine is approved to treat leprosy and has been used off-label for TB treatment.